GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a biopharmaceutical company whose fate is closely tied to its drug for the treatment of amyotrophic lateral sclerosis (ALS). Its price chart reflects the drama of the drug's approval and subsequent controversy surrounding its effectiveness, exemplifying the risks inherent in biotech.
Share prices of companies in the market segment - Neuro
Amylyx is a biopharmaceutical company focused on drugs for the treatment of neurodegenerative diseases such as ALS. We classify it as part of the Neuro sector, and the chart below reflects the dynamics of this complex and risky field of biotechnology.
Broad Market Index - GURU.Markets
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Amylyx compares to it.
Change in the price of a company, segment, and market as a whole per day
AMLX - Daily change in the company's share price Amylyx Pharmaceuticals
The volatility of Amylyx Pharmaceuticals, which focuses on treating neurodegenerative diseases, reflects the high risks of the biotech sector. Change_co is an immediate reaction to regulatory decisions and research data. This indicator forms the basis for analysis of the CNS treatment sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Amylyx Pharmaceuticals is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with AMLX, whose fate is closely tied to the success of its ALS drug, helps to assess it as a high-risk asset dependent on clinical and commercial news.
Daily change in the price of a broad market stock, index - GURU.Markets
Amylyx is a biopharmaceutical company whose story with its ALS drug exemplifies the extreme volatility of biotech, where regulatory decisions can dramatically alter a company's fate. The chart below illustrates general market fluctuations, making the Amylyx drama particularly instructive.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Amylyx Pharmaceuticals
Amylyx is a biotech company whose year-to-date performance has been extremely volatile, reflecting both successes and setbacks in clinical trials of its ALS drug. The chart below chronicles this roller coaster ride, typical of the biotech sector.
Annual dynamics of market capitalization of the market segment - Neuro
Amylyx Pharmaceuticals, Inc. is a commercial biopharmaceutical company focused on the treatment of neurodegenerative diseases. Its stock performance is highly dependent on the commercial success of its approved drug and the results of further research, as is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Amylyx is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Amylyx Pharmaceuticals
The price of Amylyx, a biopharmaceutical company, depends on its product cycle. Monthly fluctuations on the chart reflect sales data for its ALS drug, as well as news about clinical trials that could confirm or refute its effectiveness, creating high volatility.
Monthly dynamics of market capitalization of the market segment - Neuro
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its sector dynamics, shown in the chart, reflect high risks. This allows us to assess how the clinical and regulatory successes or failures of its drugs affect the company's perception.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Amylyx Pharmaceuticals is a biopharmaceutical company focused on treating neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its value depends almost entirely on the success of its drugs. The overall market price has little bearing on Amylyx's stock; its price is determined by clinical news and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, a company focused on treating neurodegenerative diseases, exhibits high volatility. Weekly stock performance depends on news about clinical trials of its drugs, regulatory decisions, and sales data, reflecting the hopes and risks in the fight against diseases like ALS.
Weekly dynamics of market capitalization of the market segment - Neuro
Amylyx Pharmaceuticals, like other biotech companies specializing in neuroscience, exhibits high volatility. The chart allows you to compare its performance with the sector to see how much of its movements are driven by general sentiment and how much by specific news about its drugs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Amylyx Pharmaceuticals is a biotech company focused on treating neurodegenerative diseases. Its shares follow a unique rhythm, driven by clinical trial results. The chart below shows how independent Amylyx's performance is from overall market fluctuations.
Market capitalization of the company, segment and market as a whole
AMLX - Market capitalization of the company Amylyx Pharmaceuticals
Amylyx Pharmaceuticals' market capitalization is a dramatic story of hope in the fight against amyotrophic lateral sclerosis (ALS). The company's stock price reflects investors' faith in its drug for this deadly disease. Its extreme volatility reflects the conflicting clinical data and regulatory decisions affecting the fate of thousands of patients.
AMLX - Share of the company's market capitalization Amylyx Pharmaceuticals within the market segment - Neuro
Amylyx Pharmaceuticals is a biopharmaceutical company focused on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its market capitalization reflects the hopes of patients and investors for its drugs. The chart shows how the market views the company's potential in this complex area of medicine.
Market capitalization of the market segment - Neuro
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases such as ALS. The chart below shows the overall market capitalization of the entire biotech sector. Its volatile dynamics reflect the high risks and enormous hopes associated with finding cures for these devastating diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Amylyx Pharmaceuticals is a company focused on treating neurodegenerative diseases such as ALS. Its market capitalization chart tells a story of hopes and disappointments in the fight against some of the most complex diseases. Its volatility reflects the challenges of clinical trials and regulatory processes.
Book value capitalization of the company, segment and market as a whole
AMLX - Book value capitalization of the company Amylyx Pharmaceuticals
The book value of Amylyx Pharmaceuticals, a developer of drugs for neurodegenerative diseases, reflects its equity and R&D assets. The chart below shows financial resources, not production capacity. The dynamics of this line reflect the company's capital management in the risky search for new treatments.
AMLX - Share of the company's book capitalization Amylyx Pharmaceuticals within the market segment - Neuro
Amylyx Pharmaceuticals develops drugs for the treatment of neurodegenerative diseases. Its core capital is intellectual property. The share of physical assets will be small, reflecting the biotech company's model, which focuses on research and clinical trials rather than owning large manufacturing plants.
Market segment balance sheet capitalization - Neuro
Amylyx Pharmaceuticals is a biopharmaceutical company focused on treating neurodegenerative diseases. Currently, its primary assets are clinical data and patents, not manufacturing capacity. The chart below shows how its book value reflects the intangible nature of its science-based business.
Book value of all companies included in the broad market index - GURU.Markets
Amylyx Pharmaceuticals' book value represents the material foundation for the fight against neurodegenerative diseases. The company's assets consist of capital required for costly clinical trials and drug inventories. The chart shows the financial and material foundation upon which drug development for ALS patients is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a company focused on treating neurodegenerative diseases. Its book value is minimal. Its market capitalization is entirely dependent on the success of its drugs, clinical trial data, and regulatory decisions. The chart reflects the roller coaster of hopes and disappointments in biotech.
Market to book capitalization ratio in a market segment - Neuro
Amylyx Pharmaceuticals is a company focused on treating neurodegenerative diseases. Its value depends on the success of one or two drugs. The chart shows how expectations for sales and future research compare with its modest tangible assets. This reflects the level of investor faith in its scientific approach compared to other neuroscience companies.
Market to book capitalization ratio for the market as a whole
Amylyx Pharmaceuticals develops drugs for the treatment of neurodegenerative diseases. The company's core value lies in its intellectual property and clinical trial results. Its market valuation reflects its expectations for approval and commercial success of its drugs. The chart illustrates how the market values biotech companies based on potential rather than current assets.
Debts of the company, segment and market as a whole
AMLX - Company debts Amylyx Pharmaceuticals
For Amylyx Pharmaceuticals, a company developing drugs to treat neurodegenerative diseases, debt is a crucial source of funding for clinical research. This chart shows the capital raised to test and bring new treatments to market. This investment in science could bring hope to millions of patients.
Market segment debts - Neuro
Amylyx Pharmaceuticals focuses on developing drugs to treat neurodegenerative diseases. For a biopharmaceutical company at this stage, debt can be critical to funding clinical trials and preparing for commercial launch. The chart below shows how Amylyx's financial strategy compares to the high risks and costs of its sector.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Amylyx Pharmaceuticals
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases such as ALS. The path from drug development to market is long and expensive. This chart shows whether the company uses debt financing. For investors, this is a key risk indicator, as failure in clinical trials with debt can be fatal.
Market segment debt to market segment book capitalization - Neuro
Amylyx Pharmaceuticals has developed a drug to treat amyotrophic lateral sclerosis (ALS), a rare and fatal disease. Developing drugs for orphan diseases is a risky process. This chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing Amylyx's financial strategy as it moves toward commercialization.
Debt to book value of all companies in the market
Amylyx Pharmaceuticals operates in the risky field of drug development. This chart shows the overall market leverage, reflecting investor risk appetite. It helps understand how easy or difficult it is for companies like Amylyx to raise debt capital for their expensive clinical trials at different stages of the economic cycle.
P/E of the company, segment and market as a whole
P/E - Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is focused on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects patient and investor hopes for a breakthrough in the treatment of serious illnesses. Its significance is highly dependent on clinical trial results and regulatory decisions, which could either pave the way for billions in sales or dash expectations.
P/E of the market segment - Neuro
Amylyx Pharmaceuticals represents the neuroscience-focused biotech sector. This chart shows the average P/E ratio for this complex industry. A company's P/E is higher than average, suggesting that investors have higher expectations for its neurodegenerative disease treatments than the sector average for its competitors.
P/E of the market as a whole
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases such as ALS. The company's success depends entirely on the approval and commercialization of its drugs. This chart reflects the overall risk appetite in the biotech industry. It helps us understand whether Amylyx's valuation is driven by clinical trial news or is supported by overall positive investor sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects investor expectations for the commercial success of its drugs and the results of ongoing clinical trials, which are key factors for future valuation.
%20P%2FE%20Amylyx%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Amylyx-Pharmaceuticals&v=1772618421109 "Chart of the company's future (projected) P/E Amylyx Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart reflects market expectations for its future profitability relative to other biopharmaceutical companies. It demonstrates investor confidence in the commercial success of its drugs and the potential for further research in this complex area of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772618421125 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). For a company whose success depends on clinical trial results, the overall market sentiment, as shown in this chart, determines the availability of investment capital to fund long-term research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772618421171 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a biopharmaceutical company focused on treating neurodegenerative diseases. Its financial performance depends primarily on the success and commercialization of its drugs. This chart shows the company's performance, whose profitability is directly linked to regulatory approvals, sales of key drugs, and new research results.
Profit of companies in the market segment - Neuro
Amylyx Pharmaceuticals is focused on developing treatments for neurodegenerative diseases such as ALS. This chart illustrates the high stakes and potential profits in the neuroscience biotech segment. Approval and commercial success of Amylyx's drugs could not only transform the lives of patients but also spur a wave of growth and investment across the industry.
Overall market profit
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases such as ALS. The company's success is determined by clinical trial results and regulatory approvals, not by broader economic trends. This exemplifies how biotech can create enormous value by solving complex medical problems, regardless of market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a biopharmaceutical company focused on treating neurodegenerative diseases such as ALS. This chart shows revenue forecasts, which are primarily driven by sales of its key drug. Analysts' expectations are based on prescribing data, regulatory approvals, and new trial results.
%20profit%20of%20the%20company%20Amylyx%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Amylyx-Pharmaceuticals&v=1772618421350 "Graph of future (projected) profit of the company Amylyx Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows overall revenue projections for the entire neuroscience segment. It helps assess the company's potential in the context of the enormous societal need and financial expectations associated with treating brain diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772618421371 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases such as ALS. Demand for these life-saving medications is not dependent on economic cycles. However, for a pharmaceutical company, this cycle is important from a healthcare perspective. During economic downturns, governments and insurance companies can put pressure on drug prices to control costs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772618421414 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is focused on developing treatments for neurodegenerative diseases such as ALS. This chart, which compares its market value to its drug sales revenue, is critical. It shows how investors view the commercial potential of its current products and whether they believe in the success of future developments in this complex area of medicine.
P/S market segment - Neuro
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The company's success depends on clinical results and approvals for its drugs. This chart reflects how investors value revenue in the biotech sector, specializing in complex diseases, demonstrating the level of confidence in Amylyx's scientific approach.
P/S of the market as a whole
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its valuation is closely tied to the success of clinical trials and drug commercialization. This chart helps investors understand how the market values biotech companies relative to overall revenue valuations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Amylyx Pharmaceuticals
Amylyx Pharmaceuticals specializes in developing treatments for neurodegenerative diseases such as ALS. This chart shows investor valuation of the company based on projected future revenue from its drugs. This valuation is highly dependent on clinical trial results, regulatory approvals, and the commercial success of the drugs in a highly competitive market.
%20P%2FS%20Amylyx%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Amylyx-Pharmaceuticals&v=1772618421554 "The graph of the company's future (projected) P/S Amylyx Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart compares investor expectations for its future revenue with the sector. A high valuation reflects expectations for the success of its drugs, while a low valuation reflects risks associated with clinical data and regulatory approval.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772618421588 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The company's future revenue depends on the market success of its drugs. This investor expectations chart is important for assessing the overall risk appetite in the biotech sector and its belief in its scientific potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772618421614 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Amylyx Pharmaceuticals
Amylyx Pharmaceuticals' revenue dynamics illustrate the commercial trajectory of its rare disease drug. The company's revenue is almost entirely dependent on sales of its drug for the treatment of amyotrophic lateral sclerosis (ALS). This chart reflects the drug's acceptance by doctors and patients, as well as its pricing and availability.
Sales of companies in the market segment - Neuro
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). This chart represents the total revenue of the entire neurodegenerative diseases market, illustrating the commercial potential of the segment in which Amylyx aims to help patients.
Overall market sales
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases such as ALS. Its success depends on the effectiveness of its drugs and their acceptance by the medical community. Demand for such drugs is inelastic, but the overall economic situation, shown in this chart, impacts the healthcare system, insurance coverage, and patients' ability to afford expensive treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is a pharmaceutical company specializing in the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its future sales are determined by the success and market acceptance of its drugs. This chart shows analyst expectations for prescription growth and the development of new therapeutic programs.
%20sales%20of%20the%20company%20Amylyx%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Amylyx-Pharmaceuticals&v=1772618421671 "Schedule of future (projected) sales of the company Amylyx Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Amylyx Pharmaceuticals is a company focused on developing treatments for neurodegenerative diseases. This chart shows the sales forecast for its drugs, primarily for the treatment of ALS. The data reflects analysts' expectations for the commercial success of the therapy in various markets and the potential for expanding its indications in the future.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772618421685 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
This chart, reflecting the biotech investment climate, is important for Amylyx Pharmaceuticals. The company is focused on treating neurodegenerative diseases. Its ability to fund expensive clinical trials and bring drugs to market is highly dependent on the overall economic situation and investor risk appetite.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772618421700 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Amylyx Pharmaceuticals
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases such as ALS. This chart reflects the company's financial performance since the launch of its first drug. Profitability is directly dependent on sales volume, pricing strategy, and success in securing approval for other indications.
Market segment marginality - Neuro
Amylyx Pharmaceuticals is a biotechnology company focused on developing drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its profitability depends on the success and commercialization of its drugs. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing Amylyx's potential in the complex field of neuroscience.
Market marginality as a whole
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases. The company's funding depends on capital inflows into the biotech sector. This chart reflects investors' overall risk appetite. During an economic recovery, it is easier to raise funds for the lengthy and expensive clinical trials Amylyx requires.
Employees in the company, segment and market as a whole
Number of employees in the company Amylyx Pharmaceuticals
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases. This chart shows the size of the team dedicated to research, clinical trials, and preparation for launch. The growth in the chart indicates progress in developing and expanding the commercial infrastructure for delivering new drugs to patients.
Share of the company's employees Amylyx Pharmaceuticals within the market segment - Neuro
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Its team consists of scientists and clinicians working on complex medical problems. The graph shows the company's share of the total number of specialists in its narrow therapeutic area, demonstrating the company's concentration of expertise and patient expectations.
Number of employees in the market segment - Neuro
Amylyx Pharmaceuticals is focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). This chart shows employment in the neuroscience research sector. The growing number of scientists and clinicians in this field reflects the high societal importance and intensity of the search for new therapies, which underpins Amylyx's mission.
Number of employees in the market as a whole
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases. Their trajectory is determined by clinical trial results and regulatory approvals. This overall employment chart reveals little about their prospects. Hiring at Amylyx accelerates following successful trials and drug approvals, not due to the state of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals is a biopharmaceutical company focused on neurodegenerative diseases. Its value is determined by the clinical success and commercial potential of its drugs. This chart reflects how the market values its intellectual property, developed by a small but highly specialized scientific team.
%20of%20the%20company%20Amylyx%20Pharmaceuticals%20(AMLX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Amylyx-Pharmaceuticals-AMLX&v=1772618422008 "Chart of market capitalization per employee (in thousands of dollars) of the company Amylyx Pharmaceuticals (AMLX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Amylyx Pharmaceuticals is a biopharmaceutical company specializing in neurodegenerative diseases such as ALS. Their value, like that of many biotechs, is determined by the success of their clinical trials and the potential of their drugs. This chart shows how the market values their focused R&D pipeline relative to their scientific team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772618422036 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases such as ALS. Marketability in this field depends on the success of clinical trials and the potential of one or two drugs. This metric illustrates how, in pharmaceuticals, a small, focused team can create a product with enormous market value, targeting serious medical problems.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772618422064 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals is a biotech company focused on treating neurodegenerative diseases, particularly ALS. This chart reflects their transition from pure R&D (when the metrics were deeply negative) to the commercial stage. It now shows how effectively their commercial and medical teams are promoting and selling their drug.
%20Chart%20Amylyx%20Pharmaceuticals%20(AMLX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Amylyx-Pharmaceuticals-AMLX&v=1772618422073 "Company Profit Per Employee (in thousands of dollars) Chart Amylyx Pharmaceuticals (AMLX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Amylyx is a biotech company focused on treating neurodegenerative diseases (ALS). This chart shows the benchmark for the "Biotech" sector. In this R&D sector, the benchmark is *extremely* volatile. It "jumps" from *deeply negative* (R&D losses) to *high* (if the drug is approved), and back again (if it is withdrawn).
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772618422109 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Amylyx Pharmaceuticals focuses on developing treatments for neurodegenerative diseases such as ALS. This is an extremely complex area of medicine. Their business is focused on clinical trials and scientific research. This chart helps us understand how the biotech model, where all value is locked into intellectual property and research data, compares to the market in terms of employee efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772618422143 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals is focused on treating neurodegenerative diseases. Since receiving approval for its first drug, revenue per employee has become a key metric for its successful launch. This chart shows how the efforts of a small marketing and sales team translate into real revenue from a life-saving drug.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Amylyx-Pharmaceuticals-AMLX&v=1772618422164 "Sales chart per company employee Amylyx Pharmaceuticals (AMLX)")
Sales per employee in the market segment - Neuro
Amylyx Pharmaceuticals is a biotech company focused on treating neurodegenerative diseases like ALS. Their productivity is unusual for a pharma company, relying on the success of their few, yet potentially breakthrough, drugs. This chart shows how effectively their team (scientists and commercial teams) brings these complex drugs to market.
Sales per employee for the market as a whole
Amylyx Pharmaceuticals (AMLX) is a biopharmaceutical company that achieved success with a drug for the treatment of ALS (amyotrophic lateral sclerosis). After receiving approval, the company quickly moved from R&D to the commercial stage. This graph is a success story for such a company. It demonstrates a dramatic leap in efficiency when a team of scientists' years of R&D efforts finally translate into a real product that generates significant revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals focuses on treating neurodegenerative diseases. Their key drug is approved for amyotrophic lateral sclerosis (ALS). This chart shows the number of bearish bets. Bearish bets may be skeptical of the drug's long-term effectiveness or its commercial success, given its high cost and competition, as well as the risks associated with the company's reliance on virtually a single product.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Amylyx-Pharmaceuticals-AMLX&v=1772618422277 "Short Shares Chart for the Company Amylyx Pharmaceuticals (AMLX)")
Shares shorted by market segment - Neuro
Amylyx (AMLX) is a pharmaceutical company focused on treating neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis). Their success depends on one or two key drugs. This chart shows the overall betting volume against the neuroscience sector. If investors are short this segment, they may doubt the effectiveness of new treatments or expect failure in clinical trials.
Shares shorted by the overall market
Amylyx (AMLX) is a neuroscience-focused biotech (ALS). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and shed risk. Biotech stocks, even those with approved drugs, often sell off when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals received approval for a drug to treat ALS (amyotrophic lateral sclerosis) based on questionable data, then withdrew it. This chart reflects the biotech roller coaster, showing extreme overbought conditions on approval hopes and deep oversold conditions after a key trial failed.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Amylyx-Pharmaceuticals-AMLX&v=1772618422432 "RSI 14 indicator chart for the company's stock Amylyx Pharmaceuticals (AMLX)")
RSI 14 Market Segment - Neuro
Amylyx Pharmaceuticals is a biotech company focused on treating neurodegenerative diseases, primarily ALS (amyotrophic lateral sclerosis). This chart measures the collective excitement and turmoil in the neuroscience biotech sector. It helps separate clinical data-driven AMLX volatility from the overall industry trend.
RSI 14 for the overall market
Amylyx (AMLX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AMLX (Amylyx Pharmaceuticals)
Amylyx Pharmaceuticals is a biopharmaceutical company focused on the treatment of neurodegenerative diseases, primarily ALS (amyotrophic lateral sclerosis). This chart shows the average analyst forecast. Their targets are based on the commercial success of approved drugs and the results of further research.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AMLX-Amylyx-Pharmaceuticals&v=1772618422458 "A chart showing analyst consensus forecasts for the expected stock price. AMLX (Amylyx Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price AMLX (Amylyx Pharmaceuticals)
Amylyx (AMLX) is a biopharmaceutical company whose ALS (amyotrophic lateral sclerosis) drug showed controversial results, leading to its recall. This chart shows their outlook. It measures the gap between the price and the consensus target, reflecting whether analysts believe the company has a future after the failure of its flagship drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AMLX-Amylyx-Pharmaceuticals&v=1772618422468 "A chart showing the difference between the consensus forecast and the actual stock price. AMLX (Amylyx Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Amylyx Pharmaceuticals, a company whose ALS (Lou Gehrig's disease) drug was withdrawn from the market after unsuccessful trials, is now exploring new development avenues. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe the company can recover from this catastrophic setback.
Analysts' consensus forecast for the overall market share price
Amylyx Pharma (AMLX) is a one-terror biotech. Their ALS drug was approved, but didn't prove effective and was withdrawn. It's an R&D project. This graph, reflecting expert expectations, is their risk appetite. After a failure, they need investor optimism (which is absent during a downturn) to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Amylyx Pharmaceuticals
Amylyx is a biotech company focused on treating neurodegenerative diseases, primarily ALS. This chart is a summary indicator of their scientific progress. It likely aggregates the commercial success (or failure) of their ALS drug, new clinical trial data, and the market's assessment of their ability to find an effective treatment in this highly complex area.
AKIMA Market Segment Index - Neuro
Amylyx (AMLX) is a single-product biotech focused on ALS (amyotrophic lateral sclerosis); the company (after controversial data) brought Relyvrio to market, but experienced setbacks in new trials. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this risky R&D bet (AMLX) differentiate it from the average pharma?
The AKIM Index for the overall market
Amylyx Pharmaceuticals is a biotech company focused on treating neurodegenerative diseases (ALS). It faced significant challenges after the failure of its key drug. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, in its transition phase, stacks up against the backdrop of overall economic trends.
